Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Daiichi Licenses ArQule Cancer Compound | Contract Pharma

What are you searching for?

Sign in
Breaking News

Daiichi Licenses ArQule Cancer Compound

ARQ 092 will be studied to identify efficacy in targeting the AKT signaling pathway

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ArQule, Inc. and Daiichi Sankyo, Co. Ltd. have entered a license agreement under which Daiichi obtains exclusive rights for the development, manufacture and marketing of ARQ 092 on a worldwide basis. ARQ 092 is the first compound to result from the companies’ November 2008 research collaboration using AKIP (ArQule Kinase Inhibitor Platform) technology to generate selective and potent small molecule kinase inhibitors.

ARQ 092 will be studied in cancer patients to identify its efficacy in targeting the AKT signaling pathway, which plays a role in regulating cell growth, survival, migration and angiogenesis. Patient enrollment in the Phase I trial is scheduled to open soon.

“The ARQ 092 collaboration builds on the success of our other partnerships with ArQule, including the co-development of our c-MET inhibitor, tivantinib, which is currently being studied in a Phase III trial as a treatment for non-squamous, non-small cell lung cancer,” said Dr. Kazunori Hirokawa, global head of the R&D Unit of Daiichi Sankyo. “In addition to our own internal R&D capabilities, our strategic alliance partnerships, such as our collaborations with ArQule, allow us to combine forces to move more programs into clinical trials toward our common goal of improving and extending lives.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics